MedTrace Logo

Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell)

NCT05574985 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 272

Last updated 2024-07-26

No results posted yet for this study

Summary

Popular topic:A Clinical Study of Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell) Overall design:The study was designed as a randomized, open and controlled study.

Study population: People aged 18 years and above and 6-15 months after the completion of basic immunization or 6-9 months after the completion of enhanced immunization with the new coronal prototype vaccine.

Test groups:Study group；Control group；Observation group ①；Observation group ②

Conditions

Interventions

BIOLOGICAL

Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell)

Injected one dose of research vaccine

BIOLOGICAL

Inactivated COVID-19 vaccine (Vero Cell)

Injected one dose of control vaccine

Sponsors & Collaborators

  • The First Affiliated Hospital of Bengbu Medical University

    collaborator OTHER

  • Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Huan Zhou, Professor · The First Affiliated Hospital of Bengbu Medical University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-08-29
Primary Completion
2022-10-09
Completion
2023-03-18

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05574985 on ClinicalTrials.gov